

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



# 利君國際醫藥(控股)有限公司

## Lijun International Pharmaceutical (Holding) Co., Ltd.

*(Incorporated in the Cayman Islands with limited liability)*  
(Stock Code: 2005)

### CLARIFICATION ANNOUNCEMENT PURSUANT TO RULE 13.09(2)(a) OF THE LISTING RULES

At the request of Lijun International Pharmaceutical (Holding) Co., Ltd. (the “**Company**”), trading in the shares of the Company on The Stock Exchange of Hong Kong Limited was halted with effect from 9:30 a.m. on 30 October 2014 pending the release of an announcement in relation to clarification of information in the announcement issued by the Company dated 29 October 2014 relating to the turnover and gross profit information for the nine months ended 30 September 2014 and resumption of trading in the shares of the Company on The Stock Exchange of Hong Kong Limited will be with effect from 1:00 p.m. on 30 October 2014

This announcement is made by Lijun International Pharmaceutical (Holding) Co., Ltd. (the “**Company**”) pursuant to Rule 13.09(2)(a) of the Rules Governing the Listing of Securities on the Stock Exchange of Hong Kong Limited (“**Listing Rules**”) and the Inside Information Provisions (as defined under the Listing Rules) under Part XIVA of the Securities and Future Ordinance (Chapter 571, Laws of Hong Kong) (the “**SFO**”).

As stated in the announcement issued by the Company dated 29 October 2014 relating to the turnover and gross profit information for the nine months ended 30 September 2014, the following amendments have been made:

Turnover of intravenous infusion solution segment for the first nine months in 2014 increased by approximately 19.4% as compared with the same period of 2013 to HK\$1,522 million, with gross profit margin of 50.2% (for the nine months ended 30 September 2013: 45.3%). Among which, sales of Non-PVC Soft Bag infusion solution (including the subcontracting products) was HK\$838.0 million, representing 59.7% of the total sales of intravenous infusion solution and an increase of 39.7% as compared with the same period of 2013; sales of PP Plastic Bottle infusion solution (including the subcontracting products) was HK\$403.1 million, representing 28.7% of the total sales of intravenous infusion solution and an increase of 13.8% as compared with the same period of 2013.

**Shareholders of the Company and potential investors are advised to exercise caution when dealing in the shares of the Company.**

By Order of the Board  
Chan Ka Kit  
*Company Secretary*

Hong Kong, 30 October 2014

*As at the date of this announcement, the Board comprises Mr. Qu Jiguang, Mr. Wang Xianjun and Mr. Duan Wei as executive Directors, and Mr. Wang Yibing, Mr. Leung Chong Shun and Mr. Chow Kwok Wai as independent non-executive Directors.*